Novartis related Press Releases
The University of Siena and Novartis Vaccines launch the first Masters program in Vaccinology and Clinical Development
The University of Siena and Novartis Vaccines launch the first Masters program in Vaccinology and Clinical Development
The first international pool of experts engaged in the on-site struggle... Read more...
Novartis names Jonathan Symonds deputy CFO and CFO designate
Novartis names Jonathan Symonds deputy CFO and CFO designate
Symonds joins Novartis from Goldman Sachs starting September 1, 2009
Basel, May 13, 2009 - Novartis announced today that Jonathan
PDI, Inc. Announces Termination of Promotion Agreement with Novartis Corporation
PDI, Inc. Announces Termination of Promotion Agreement with Novartis Corporation4/23/2009 SADDLE RIVER, N.J.--(BUSINESS WIRE)--PDI, Inc. (NASDAQ: PDII - News), a pioneer in providing contract sales
... Read more...Novartis Animal Health launches Zolvix, a new de-worming product for sheep
Novartis Animal Health is listening to farmers - and the results are a significant breakthrough in sheep worm control worldwide Counting sheepThere are nearly 1.8 billion sheep worldwide. The animals
... Read more...Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US Data indicates what physicians value from pharmaceutical companies, and which companies are getting
... Read more...Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug; Portola to Receive $500 Million in Milestones
Novartis AG to Pay Portola Pharmaceuticals, Inc. $75 Million for Anti-clotting Drug; Portola to Receive $500 Million in Potential Milestone Payments Plus Royalties on Future Sales SOUTH SAN
... Read more...Extavia's Launch Foreshadows Novartis' Future Intentions in the Multiple Sclerosis Market, According to Cutting Edge Information
Extavia's Launch Foreshadows Novartis' Future Intentions in the Multiple Sclerosis Market, According to Cutting Edge Information MARKETWIRE Feb 05, 2009RESEARCH TRIANGLE PARK, NCMARKET WIRE Novartis'
... Read more...Novartis and Medicines for Malaria Venture launch Coartem® Dispersible, the first ACT* developed for children
Novartis and Medicines for Malaria Venture launch Coartem® Dispersible, the first ACT* developed for children suffering from malaria
More children die from malaria than any other patient group -
... Read more...Novartis International AG (VTX:NOVN) US Department Of Health And Human Services Awards Novartis USD 486 million Contract
Novartis International AG (VTX:NOVN) US Department Of Health And Human Services Awards Novartis USD 486 million Contract To Build Manufacturing Facility For Pandemic Flu Vaccine Novartis
... Read more...FORMA Therapeutics Announces Collaboration with Novartis to Develop Inhibitors of Protein-Protein Interactions
FORMA Therapeutics Announces Collaboration with Novartis to Develop Inhibitors of Protein-Protein Interactions FORMA eligible to receive over $200 million in potential fees and milestones CAMBRIDGE,
... Read more...Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
